Identifying the Best Populations to Target, De-Risking Discovery and Early-Stage Development

1 minute read

Published: June 3rd, 2026

About This Webinar

In this session, we explore real-world use cases where AI and LLMs (Large Language Models) have been applied to explore large data sources such as omics, literature, and real-world data (RWD). We explore how AI can help identify optimal target populations, endpoints, and even support drug repurposing.

Speaker:

Billy Amzal, Ph.D.
Head of Strategic Consulting, Phastar

Key Takeaways:

  • How AI helps explore large datasets for drug development
  • De-risking clinical research using AI for precision care
  • Real-world examples of AI transforming early-stage development
Complete the form below to access the recording and slides:

Related articles

A Systematic Review into the Use of Bayesian Methods in Clinical Trials

A Systematic Review into the Use of Bayesian Methods in Clinical Trials

June 30th, 2026 1 minute read

About This Webinar Bayesian methods continue to gain momentum as an alternative approach to traditional clinical tria...

Bridging the Efficacy Effectiveness Gap in Rare Diseases with RWD

Bridging the Efficacy Effectiveness Gap in Rare Diseases with RWD

June 29th, 2026 1 minute read

About This Webinar Drug development in rare diseases requires the most efficient use of limited data, across both cli...

Driving Clinical Research with AI: From Early Discovery to Regulatory-Grade Insights

Driving Clinical Research with AI: From Early Discovery to Regulatory-Grade Insights

June 28th, 2026 1 minute read

Join us for a transformative three-part webinar series, “Driving Clinical Research with AI,” where indust...